| BioNxt: Beyond the Pill.. Could Dissolvable Film Technology Change Multiple Sclerosis Treatment? | Join Lyndsay Malchuk on Market Frontlines for an interview with Hugh Rogers, Co-Founder, CEO and Director of BioNxt Solutions Inc. (CSE: BNXT | OTCQB: BNXTF | FSE: BXT). BioNxt develops sublingual dissolvable... ► Artikel lesen |
| BioNxt Solutions Inc. Announces Non-Brokered Private Placement of Units | Not for distribution to U.S. newswire services or for dissemination in the United States. VANCOUVER, BC / ACCESS Newswire / November 16, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT)... ► Artikel lesen |
| Spannendes Pharma-Duell: Wer startet jetzt durch - BioNxt Solutions, Bayer oder Novo Nordisk? | Neue Wirkstoffe, erweiterte Indikationen und nutzerfreundlichere Darreichungsformen bestimmen die Dynamik im globalen Pharmamarkt. BioNxt Solutions konzentriert sich auf neuartige Arzneifilme und arbeitet... ► Artikel lesen |
| iBio, Inc.: iBio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update | SAN DIEGO, Aug. 28, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology company developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary... ► Artikel lesen |
| iBio, Inc.: iBio Strengthens Clinical Leadership with Appointment of Endocrinologist Molly Carr as Chief Medical Officer | SAN DIEGO, Aug. 04, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary... ► Artikel lesen |
| iBio, Inc.: iBio Reports Single Dose of IBIO-610 Achieved Near-Complete Active Activin E Inhibition Through Eight Weeks in Obese NHP Study | Single-dose IBIO-610 achieved up to 98% inhibition of active Activin E through eight weeks, supporting a differentiated, long-acting antibody approach When combined with semaglutide, IBIO-610 drove... ► Artikel lesen |
| Beta Bionics, Inc.: Beta Bionics Announces Agreement Integrate the iLet Bionic Pancreas and mint with Senseonics' Eversense 365 | IRVINE, Calif., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced a partnership... ► Artikel lesen |